Zacks Research Weighs in on Humana’s Q4 Earnings (NYSE:HUM)

Humana Inc. (NYSE:HUM) – Research analysts at Zacks Research cut their Q4 2024 EPS estimates for shares of Humana in a note issued to investors on Wednesday, November 13th. Zacks Research analyst D. Chatterjee now anticipates that the insurance provider will post earnings of ($2.31) per share for the quarter, down from their prior forecast of ($1.64). The consensus estimate for Humana’s current full-year earnings is $15.86 per share. Zacks Research also issued estimates for Humana’s Q3 2025 earnings at $3.72 EPS, Q4 2025 earnings at $0.30 EPS, FY2025 earnings at $16.65 EPS, Q1 2026 earnings at $6.27 EPS, Q2 2026 earnings at $5.51 EPS, Q3 2026 earnings at $2.90 EPS and FY2026 earnings at $14.96 EPS.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.48 by $0.68. Humana had a return on equity of 13.20% and a net margin of 1.18%. The business had revenue of $29.30 billion during the quarter, compared to analysts’ expectations of $28.66 billion.

Several other equities analysts have also commented on HUM. JPMorgan Chase & Co. raised their target price on shares of Humana from $332.00 to $396.00 and gave the company a “neutral” rating in a report on Wednesday, August 21st. Stephens restated an “equal weight” rating and set a $250.00 price objective on shares of Humana in a research report on Wednesday, October 9th. Barclays upped their target price on Humana from $250.00 to $253.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. Jefferies Financial Group lowered Humana from a “buy” rating to a “hold” rating and decreased their price target for the company from $519.00 to $253.00 in a research note on Monday, October 7th. Finally, Royal Bank of Canada dropped their price objective on Humana from $400.00 to $265.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Twenty analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, Humana has a consensus rating of “Hold” and an average target price of $315.86.

Humana Stock Down 2.6 %

HUM stock opened at $275.67 on Monday. Humana has a 52 week low of $213.31 and a 52 week high of $527.18. The business has a 50-day simple moving average of $281.36 and a 200 day simple moving average of $331.94. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. The company has a market cap of $33.19 billion, a PE ratio of 24.42, a price-to-earnings-growth ratio of 2.17 and a beta of 0.52.

Hedge Funds Weigh In On Humana

Hedge funds have recently made changes to their positions in the stock. Mendota Financial Group LLC increased its position in Humana by 9.2% during the 2nd quarter. Mendota Financial Group LLC now owns 319 shares of the insurance provider’s stock valued at $119,000 after purchasing an additional 27 shares during the period. Capital Advisors Ltd. LLC increased its position in shares of Humana by 17.0% during the second quarter. Capital Advisors Ltd. LLC now owns 213 shares of the insurance provider’s stock worth $80,000 after buying an additional 31 shares during the period. CarsonAllaria Wealth Management Ltd. increased its position in shares of Humana by 111.4% during the second quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock worth $28,000 after buying an additional 39 shares during the period. Moors & Cabot Inc. raised its stake in Humana by 2.5% during the third quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider’s stock worth $519,000 after buying an additional 40 shares during the last quarter. Finally, Harbour Investments Inc. lifted its holdings in Humana by 10.5% in the second quarter. Harbour Investments Inc. now owns 432 shares of the insurance provider’s stock valued at $161,000 after buying an additional 41 shares during the period. 92.38% of the stock is currently owned by institutional investors.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be given a $0.885 dividend. The ex-dividend date is Tuesday, December 31st. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.28%. Humana’s dividend payout ratio (DPR) is presently 31.36%.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.